Article Text

PDF

Brocresine in Parkinson's disease
  1. Patricia M. Howse,
  2. W. B. Matthews
  1. Department of Clinical Neurology, the Churchill Hospital, Headington, Oxford

    Abstract

    Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease. The search for useful decarboxylase inhibitors therefore need not be limited to agents that do not pass the blood/brain barrier.

    Statistics from Altmetric.com

    Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.